GlassScriptPhysician profile
Reed H Jarvis
NPI 1578762449
$15,931.94
in general payments reported to CMS, 2019-2025
20 companies · $497 in 2025
The $497 reported for 2025 was more than what 77% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $311 · 2021: $1,468 · 2022: $2,105 · 2023: $1,752 · 2024: $9,326 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,199.91 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,375.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $7,993.19 | 2024 | M22 |
| Alcon Vision LLC | $4,926.51 | 2019-2025 | Precision 1, Dailies Total1, Air Optix Color |
| Sun Pharmaceutical Industries INC. | $698.10 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $454.55 | 2022-2025 | Infuse, Xiidra, Miebo |
| Oyster Point Pharma, INC. | $344.58 | 2022-2025 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $269.40 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $243.64 | 2019-2023 | |
| Allergan, INC. | $232.30 | 2019-2022 | |
| Coopervision INC. | $225.20 | 2021-2025 | Myday Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $180.97 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $68.90 | 2021-2022 | |
| Lombart Brothers, INC. | $50.00 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $49.27 | 2023 | Axert |
| Astellas Pharma US INC | $48.16 | 2023-2024 | Izervay |
| Shire North American Group INC | $42.70 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $29.88 | 2022 | |
| Dompe US, INC. | $29.00 | 2025 | Oxervate |
| Horizon Therapeutics Plc | $17.08 | 2023 | Tepezza |
| Harrow Eye, LLC | $15.79 | 2024 | Vevye |
| Biotissue Holdings INC. | $12.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reed Jarvis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.